Presented by: University of Kentucky Department of Pathology

“The inflamed heart – an update”

William O’Connor, MD

Professor

Department of Pathology

University of Kentucky

       Thursday, October 22, 2026

12:00 – 1:00pm

In-Person MS 147 or Zoom: https://us06web.zoom.us/j/88974250308

Passcode: 710932

 Use the QR code to register for this Grand Rounds if you have not already registered.

At the completion of this lecture attendees should be able to:

• Add to the differential of cardiac inflammation and mechanisms of injury
• Clarify using histopathology and immunohistochemistry findings how endomyocardial heart  biopsy can distinguish among causes of life threatening microscopic inflammation of heart muscle (Myocarditis).
• Recognize importance of timely, and detailed clinical, imaging, and laboratory findings for accurate diagnosis for patient care by Cardiologist.
•  Expand the differential slide based diagnostic categories to include Hypersensitivity to patient heart medications, Chemotherapy effects and recent CAR T Cell and  Immune checkpoint Inhibitor therapy for Cancer patients.

Disclosure of Financial Interest Summary to Learners

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months.  An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have a relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation